REFRACTORY MULTIPLE MYELOMA

This study is testing whether a different dosing schedule for the drug elranatamab can make treatment safer and allow patients with advanced multiple myeloma to receive it as outpatients. The trial involves 40 patients whose cancer has returned or stopped responding to at least t…

This early-stage study is testing the safety and best dose of a new two-drug combination for multiple myeloma that has come back or stopped responding to other treatments. The trial combines an oral pill (iberdomide) that targets cancer cell proteins with an injected immunotherap…

This study is testing a combination of four medications to control multiple myeloma that has returned or stopped responding to prior treatments. It will involve about 43 adults whose cancer progressed after standard therapies. The main goal is to see how well this specific drug c…

This early-stage trial is testing whether combining three existing drugs—elotuzumab, CC-92480, and dexamethasone—is safe and effective for people with multiple myeloma that has returned or stopped responding to treatment. The study involves 27 patients whose cancer has progressed…

This study is testing whether a combination of three drugs (elotuzumab, iberdomide, and dexamethasone) can help control multiple myeloma in patients whose cancer has returned or stopped responding to many treatments, including a recent CAR-T cell therapy. The goal is to see if th…

This early-stage trial is testing a new treatment for multiple myeloma that has returned or stopped responding to standard therapies. Doctors will collect patients' own immune cells, use CRISPR gene-editing technology to reprogram them to attack cancer, then infuse them back into…

This study is testing whether adding a new drug called iberdomide to an existing treatment (belantamab mafodotin and dexamethasone) is safe and more effective for people with multiple myeloma that has returned or stopped responding to other therapies. The trial will first find th…

This study is testing whether adding two drugs, dasatinib and quercetin, to a powerful cell therapy (CAR-T) can better treat multiple myeloma that has come back or stopped responding to other treatments. The goal is to see if this combination helps the CAR-T therapy work more eff…

This early-stage study is testing whether a personalized cancer vaccine, made from a patient's own tumor and immune cells, is safe and works well when given alongside an approved drug called elranatamab. The goal is to see if this combination can better control multiple myeloma i…

This early-stage study is testing a new type of cell therapy designed to attack two different targets on cancer cells. It is for patients with multiple myeloma or a type of lymphoma that has come back or stopped responding to standard treatments. The main goal is to see if this t…

This study is testing a new combination of four medications for people whose multiple myeloma has come back or stopped responding to prior treatments. The main goal is to see if this combination can shrink the cancer so effectively that it becomes undetectable by very sensitive t…

This study is testing whether the drug elranatamab can help prevent multiple myeloma from returning or worsening in patients who have already received a specialized CAR-T cell therapy called idecabtagene vicleucel. The research involves about 32 adults with relapsed or hard-to-tr…

This early-stage study is testing a new combination of three drugs for patients with multiple myeloma that has come back or stopped responding to standard treatments. The main goals are to find the safest and most effective dose and to see how well the combination works. The tria…

This study is testing if different doses and timing of the drug belantamab mafodotin can work better for people with multiple myeloma that has come back or stopped responding to other treatments. The drug is designed to target and kill myeloma cells. Researchers want to see if th…

This early-stage trial is testing a new type of CAR T-cell therapy called TriPRIL for adults with multiple myeloma that has returned or stopped responding to standard treatments. Researchers will give patients a single infusion of their own modified immune cells to try to fight t…

This study is testing whether doctors can safely lower the dose and frequency of a cancer drug called linvoseltamab for patients with multiple myeloma that has returned or stopped responding to other treatments. The goal is to see if less medicine can still control the cancer whi…

This study is testing whether using a drug called talquetamab before a personalized cell therapy (cilta-cel) is safe and feasible for people with multiple myeloma that has returned or stopped responding to treatment. The research will enroll 31 adults who have already tried at le…

This study is testing a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—to see if it can control multiple myeloma that has come back or stopped responding to other treatments and has spread to form tumors in soft tissues or organs. It will involve about 28 …

This study is testing a combination of four medications for people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see how well this new combination controls the cancer and for how long. About 50 participants will receive the trea…

This study aims to find the best way to prevent taste changes (dysgeusia) that can occur when taking the myeloma drug talquetamab. About 130 adults with relapsed or hard-to-treat multiple myeloma will try different preventive treatments. Researchers will carefully measure taste c…

This study is testing whether a personalized exercise program in the weeks before CAR-T cell therapy can help older adults with recurrent multiple myeloma. Researchers want to see if this 'prehabilitation' improves patients' physical strength, fitness, and quality of life both be…